LexBlog IP

AUGUST 30, 2023

market on March 7, 2025, if approved by FDA. J&J also recently filed a confidential settlement and license agreement to terminate a Samsung Bioepis challenge to all claims of U.S.

Settlement 52

Settlement Confidentiality Marketing Marketing 52

SpicyIP

OCTOBER 31, 2023

Image from here Recently, the Print reported that Novartis and Eli Lilly have voiced their opposition to the idea of compulsory licensing (“ CL ”) for breast cancer medications, Ribociclib and Abemaciclib. It also says that no licenses were given out. crore in revenue from 8,000 units sold, its first year on the market.

Licensing 72

Licensing Government Reporting Patent 72

Bio Law Blog

JUNE 21, 2020

settled three Inter Partes Review (IPR) proceedings concerning patents covering Alexion’s blockbuster humanized monoclonal antibody drug Soliris®, with Amgen obtaining a royalty-free license for marketing a biosimilar prior to expiration of the patents at issue. and Alexion Pharmaceuticals Inc. an eculizumab product.

Marketing 52

Marketing Marketing Settlement Patent 52

LexBlog IP

FEBRUARY 23, 2024

The settlements cover Canada, the European Economic Area, and Japan, clearing the way for Alvotech to launch AVT04 in those markets, where AVT04 has already received regulatory approval. Alvotech has commercial partners for AVT04 in each of the aforementioned markets. Per the settlement agreement, AVT04 can be marketed in the U.S.,

Settlement 52

Settlement Marketing Marketing Licensing 52

LexBlog IP

JANUARY 12, 2023

Coherus plans to file an abbreviated Biologics License Application (aBLA) with the FDA later this year and intends to launch the product at EYLEA biosimilar market formation, currently expected to be in 2025. The parties expect to complete the transaction in Q1 2023.

Marketing 52

Marketing Marketing Licensing Intellectual Property 52

Velocity of Content

MAY 25, 2023

The agreement enables MARC to include CCC’s comprehensive rights catalog in the licenses it offers to educational and academic institutions in Malaysia. MARC is an independent, not-for-profit organization acting as a collective licensing organization on behalf of publishers, authors, and visual creators in Malaysia.

Licensing 52

Licensing Journalism Copyright Marketing 52

LexBlog IP

SEPTEMBER 28, 2023

has announced an exclusive licensing agreement with Tonghua Dongbao Pharmaceuticals Co., to commercialize several of Abbott’s oncology, women’s health, and respiratory disease biosimilars for emerging markets in Latin America, Southeast Asia, the Middle East, and Africa. Insulin Biosimilars: Meitheal Pharmaceuticals, Inc.

Marketing 52

Marketing Marketing Contracts Registration 52

SpicyIP

JULY 8, 2024

CGPDTM Announces Dates for 2025 Trademark and Patent Agent Exams Dates for Trademark and Patent Agent Exams 2025 have been announced by the CGPDTM. The Trademark Agent Exam is likely to be held on January 04, 2025 and the Patent Agent Exam is likely to be held on January 5, 2025. Microsoft Technology Licensing LLC v.

Invention 59

Invention Art Trademark Patent Application 59

Herbert Smith Freehills

OCTOBER 14, 2021

"Abbisko is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies and has strategically designed and developed a diversified pipeline of 12 programs with global R&D and commercialisation rights and selectively in-licensed two programs.". from 2025 to 2030. HK?????????06609.HK????????06669.HK??.

Marketing 52

Marketing Marketing Licensing Publishing 52

LexBlog IP

NOVEMBER 5, 2023

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. According to a reported statement from Amgen, its settlement agreement with Janssen allows Amgen to sell WEZLANA “no later than January 1, 2025.”

Marketing 40

Marketing Marketing Government Litigation 40

IAM Magazine

SEPTEMBER 23, 2021

A new high-level policy calls for growth by a metric that includes not just royalty receipts but also payments to foreign IP owners.

IP 52

IP Licensing Marketing Marketing 52

LexBlog IP

FEBRUARY 1, 2024

In October 2023, Accord settled with Janssen Biotech under confidential terms that would allow Accord to launch its proposed ustekinumab biosimilar no later than May 15, 2025, pending FDA approval.

Confidentiality 52

Confidentiality Reporting Licensing Marketing 52

LexBlog IP

JANUARY 25, 2024

FDA Approvals In 2023, there were 23 FDA approvals of Biologic License Applications , including for Vertex’s CASGEVY and Bluebird’s LYFGENIA, the first cell-based gene therapies for the treatment of sickle cell disease. As we kick off 2024, we reflect on regulatory developments in the biologics and biosimilars space in 2023.

Marketing 52

Marketing Marketing Licensing Litigation 52

IAM Magazine

SEPTEMBER 23, 2021

A new high-level policy calls for growth by a metric that includes not just royalty receipts but also payments to foreign IP owners.

IP 52

IP Licensing Marketing Marketing 52

SpicyIP

MARCH 15, 2024

This post does not, in any manner, get into the arena of willingness or unwillingness of defendants to enter into a licensing agreement. If the trial spills over to 2025, the defendants will have to bear the cost for that as well. I pose questions (rather than offer comments) with regard to the Court’s approach on bank guarantees.

Patent Infringement 59

Patent Infringement Settlement Patent Licensing 59

The IPKat

NOVEMBER 14, 2022

a wise cat that care about environment kindly provided in CC0 Public Domain license by Pixhere.com) Having to make a selection among the many topics covered, this GuestKat finds it interesting to note that during the conference the EPO case G2/21 on 'plausibility', was repeatedly discussed from different angles.

IP 74

IP Marketing Marketing Confidentiality 74

LexBlog IP

JANUARY 16, 2023

The European Commission expressed its hope that the provisions of the regulation will enter into force across all EU member states in 2025. If approved, the EHDS proposal would introduce a new regime for the compulsory licensing of health data to third parties.

Intellectual Property 52

Intellectual Property Confidentiality Business Advertising 52

LexBlog IP

JANUARY 17, 2024

Any reporting company that is created or registered before January 1, 2024, must file a BOI report no later than January 1, 2025. The CTA takes effect on January 1, 2024.

Reporting 52

Reporting Business Editing Ownership 52

LexBlog IP

AUGUST 29, 2023

Any reporting company that is created or registered before January 1, 2024, must file a report no later than January 1, 2025. Reports will not be accepted prior to January 1, 2024. FinCEN is currently in the process of creating the specific reporting system and additional regulations surrounding the CTA.

Reporting 52

Reporting Ownership Business Editing 52

Herbert Smith Freehills

SEPTEMBER 10, 2021

In early 2020, a group of legislators submitted to the House of Representatives to prohibit the installation and operation of coal-fired power plants nationwide by 2025. Bill 3729/2004 was also approved by Congress, which creates more flexible and simpler processes for environmental licensing within Brazil. . Developing Initiatives.

Contracts 52

Contracts Government Law Marketing 52

Herbert Smith Freehills

SEPTEMBER 10, 2021

In early 2020, a group of legislators submitted to the House of Representatives to prohibit the installation and operation of coal-fired power plants nationwide by 2025. Bill 3729/2004 was also approved by Congress, which creates more flexible and simpler processes for environmental licensing within Brazil. . Developing Initiatives.

Contracts 52

Contracts Government Law Marketing 52

Kluwer Copyright Blog

DECEMBER 13, 2023

In this post, the focus is on the unlicensed use of copyright-protected works in the context of training GenAI models, where such use could jeopardise the market for those particular expressions (see Sobel ). It appears that a one-size-fits-all approach to training data licensing may not be optimal for the ASEAN.

Copyright 49

Copyright IP Music Licensing 49

Copyright Lately

DECEMBER 4, 2023

Wait until 2025. Wheen will remain protected until January 1, 2025. Extending Rights in Public Domain Works There are a few recognized methods that publishers and other rightsholders use to retain market share even after a work has entered the public domain. Can’t read German? translation by A.W.

Public Domain 117

Public Domain Music Copyright Publishing 117

LexBlog IP

AUGUST 14, 2023

Reporting Companies created before January 1, 2024, have one year (until January 1, 2025) to file the required information. Reporting Companies created on or registered prior to January 1, 2024, are not required to report their Company Applicant. When do I Need to Report By? The rule goes into effect January 1, 2024.

Business 52

Business Ownership Reporting Registration 52

The IPKat

AUGUST 13, 2024

Upcoming events Assimilate IP Autumn Courses and Webinars : Protecting Confidential Information, Trade Secrets and Know How : 11 September 2024 Freedom to Operate for Life Sciences and Pharma : 25 & 26 September 2024 Patent and Know How Licensing : 9 & 10 October 2024 IP Essentials – Patent or Trade Secret? Call for abstracts.

Intellectual Property 61

Intellectual Property IP Journalism Confidentiality 61

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

At the same time, market uptake of biosimilars in the United States continued to increase, suggesting that there is room for expansion of biosimilars in the U.S. For the first time since FDA licensed the first biosimilar, Sandoz’s Zarxio ® (filgrastim-sndz), in 2015, the United States saw a decrease in annual biosimilar approvals in 2020.

Litigation 52

Litigation Settlement Marketing Marketing 52

Fish & Richardson Trademark & Copyright Thoughts

DECEMBER 2, 2020

billion by 2025. [ii] The 2018 Farm Bill led to widespread availability of products containing CBD, which are commonly marketed as dietary supplements, drugs, food, and cosmetics. Contracts, such as cannabis patent licenses, could also be unenforceable under federal law. billion, with an expected increase to $29.7

IP 52

IP Registration Trademark Branding 52

TorrentFreak

DECEMBER 6, 2023

This is a direct result of the territorial licensing deals the entertainment industry is built on. Many PlayStation users were reminded of these licensing complications a few days ago when they were informed that several purchased movie titles will disappear from their libraries. That frustration can, in turn, fuel piracy.

Licensing 80

Licensing Reporting Cinema Marketing 80

TorrentFreak

DECEMBER 17, 2023

Running for four seasons from the 2025-26 campaign, the deal will see broadcasters Sky and TNT take the live games and the BBC continue with its popular highlights package. Amazon, which has been licensing Premier League games since 2019, hoping to drive customers towards its Prime service, wasn’t awarded a single match.

Licensing 86

Licensing Copyright Marketing Marketing 86

The IPKat

FEBRUARY 4, 2022

The EU Toolbox is part of the EU Strategy to tackle Organised Crime 2021-2025. The EC reports that despite efforts to battle counterfeit goods, the market is still thriving, with an increase of detained articles at EU borders. Unported License.

Due Diligence 130

Due Diligence IP Technology Licensing 130

LexBlog IP

DECEMBER 28, 2023

Reddy’s”) to license Dr. Reddy’s proposed biosimilar abatacept for the development and commercialization of COYA 302 for the treatment of neurodegenerative conditions. Ltd. (“THDB”) to market three biosimilars of the top selling branded insulins in the United States – asprat, lispro and glargine.

Licensing 52

Licensing Reporting Marketing Marketing 52

LexBlog IP

APRIL 25, 2023

“[The] Government [is] committed to delivering a Data Marketplace by 2025, to provide a single front door for Government users to discover public sector data. and] will explore how this could be expanded. ” ICO should update its guidance for processing activities relating to AI as a service (AIaaS).

Technology 52

Technology Government Reporting Intellectual Property 52

LexBlog IP

AUGUST 25, 2023

In effect, the Maximum Fair Price (MFP) must be set at no more than 40-75% (depending on how long the product has been on the market without generic or biosimilar competition) of what the drug’s average manufacturer price was in the year 2021. Beginning in 2025, CMS will publish its selected drugs on February 1.)

Government 40

Government Marketing Marketing Publishing 40